| Novel antisense therapy targeting microRNA-132 in patients with heart failure: results of a first-in-human Phase 1b randomized, double-blind, placebo-controlled study J Täubel, W Hauke, S Rump, J Viereck, S Batkai, J Poetzsch, L Rode, ... European heart journal 42 (2), 178-188, 2021 | 235 | 2021 |
| Lamotrigine does not prolong QTc in a thorough QT/QTc study in healthy subjects R Dixon, S Job, R Oliver, D Tompson, JG Wright, K Maltby, U Lorch, ... British journal of clinical pharmacology 66 (3), 396-404, 2008 | 113 | 2008 |
| Pharmacokinetics of concentrated naloxone nasal spray for opioid overdose reversal: Phase I healthy volunteer study R McDonald, U Lorch, J Woodward, B Bosse, H Dooner, G Mundin, ... Addiction 113 (3), 484-493, 2018 | 89 | 2018 |
| Phase 1/2 study of lumasiran for treatment of primary hyperoxaluria type 1: a placebo-controlled randomized clinical trial Y Frishberg, G Deschênes, JW Groothoff, SA Hulton, D Magen, ... Clinical Journal of the American Society of Nephrology 16 (7), 1025-1036, 2021 | 54 | 2021 |
| Thorough QT study of the effect of oral moxifloxacin on QTc interval in the fed and fasted state in healthy Japanese and Caucasian subjects J Taubel, G Ferber, U Lorch, V Batchvarov, I Savelieva, AJ Camm British Journal of Clinical Pharmacology 77 (1), 170-179, 2014 | 52 | 2014 |
| Thorough QT study of the effect of intravenous amisulpride on QTc interval in Caucasian and Japanese healthy subjects J Täubel, G Ferber, G Fox, S Fernandes, U Lorch, AJ Camm British journal of clinical pharmacology 83 (2), 339-348, 2017 | 49 | 2017 |
| Bupivacaine extended release liposome injection does not prolong QTc interval in a thorough QT/QTc study in healthy volunteers A Naseem, T Harada, D Wang, R Arezina, U Lorch, E Onel, AJ Camm, ... The Journal of Clinical Pharmacology 52 (9), 1441-1447, 2012 | 48 | 2012 |
| Safety, Tolerability, Pharmacokinetics, and Antimalarial Activity of the Novel Plasmodium Phosphatidylinositol 4-Kinase Inhibitor MMV390048 in Healthy Volunteers P Sinxadi, C Donini, H Johnstone, G Langdon, L Wiesner, E Allen, ... Antimicrobial agents and chemotherapy 64 (4), 10.1128/aac. 01896-19, 2020 | 46 | 2020 |
| Levofloxacin can be used effectively as a positive control in thorough QT/QTc studies in healthy volunteers J Taubel, A Naseem, T Harada, D Wang, R Arezina, U Lorch, AJ Camm British journal of clinical pharmacology 69 (4), 391-400, 2010 | 42 | 2010 |
| First‐in‐human clinical trial to assess the safety, tolerability and pharmacokinetics of P218, a novel candidate for malaria chemoprotection MF Chughlay, E Rossignol, C Donini, M El Gaaloul, U Lorch, S Coates, ... British journal of clinical pharmacology 86 (6), 1113-1124, 2020 | 35 | 2020 |
| The suppression of gastro‐oesophageal reflux by alginates PW Dettmar, FC Hampson, J Taubel, U Lorch, LM Johnstone, J Sykes, ... International journal of clinical practice 61 (10), 1654-1662, 2007 | 34 | 2007 |
| Similar rivastigmine pharmacokinetics and pharmacodynamics in Japanese and white healthy participants following the application of novel rivastigmine patch G Lefèvre, M Büche, G Sedek, S Maton, A Enz, U Lorch, C Sagan, ... The Journal of Clinical Pharmacology 49 (4), 430-443, 2009 | 30 | 2009 |
| Insulin at normal physiological levels does not prolong QTc interval in thorough QT studies performed in healthy volunteers J Taubel, U Lorch, G Ferber, J Singh, VN Batchvarov, I Savelieva, ... British journal of clinical pharmacology 75 (2), 392-403, 2013 | 29 | 2013 |
| A first‐in‐man safety and pharmacokinetics study of nangibotide, a new modulator of innate immune response through TREM‐1 receptor inhibition V Cuvier, U Lorch, S Witte, A Olivier, S Gibot, I Delor, JJ Garaud, M Derive, ... British journal of clinical pharmacology 84 (10), 2270-2279, 2018 | 27 | 2018 |
| The power of phase I studies to detect clinical relevant QTc prolongation: a resampling simulation study G Ferber, U Lorch, J Täubel BioMed Research International 2015, 2015 | 23 | 2015 |
| Time-and race-specific haematological reference intervals for healthy volunteer trials: a retrospective analysis of pooled data from multiple phase I trials S Coates, D Wang, T Pierscionek, S Fernandes, D Djumanov, U Lorch, ... Frontiers in Pharmacology 11, 314, 2020 | 22 | 2020 |
| Three steps to writing adaptive study protocols in the early phase clinical development of new medicines U Lorch, M O’Kane, J Taubel BMC Medical Research Methodology 14, 1-9, 2014 | 22 | 2014 |
| Pharmacokinetics and pharmacogenetics of the MEK1/2 inhibitor, selumetinib, in Asian and Western healthy subjects: a pooled analysis AW Dymond, C Elks, P Martin, DJ Carlile, G Mariani, S Lovick, Y Huang, ... European Journal of Clinical Pharmacology 73, 717-726, 2017 | 16 | 2017 |
| Pharmacokinetics, safety and cognitive function profile of rupatadine 10, 20 and 40 mg in healthy Japanese subjects: a randomised placebo-controlled trial J Täubel, G Ferber, S Fernandes, U Lorch, E Santamaría, I Izquierdo PloS one 11 (9), e0163020, 2016 | 15 | 2016 |
| Single doses up to 800 mg of E-52862 do not prolong the QTc interval–A retrospective validation by pharmacokinetic-pharmacodynamic modelling of electrocardiography data … J Täubel, G Ferber, U Lorch, D Wang, M Sust, AJ Camm PLoS One 10 (8), e0136369, 2015 | 15 | 2015 |
